Therefore, in the development of antitumor drugs targeting cytoskeletal proteins, compounds that modify the mechanoresponsiveness of cancer cells by altering their actin-binding activity may provide an additional therapeutic strategy [66].In future studies, we must first obtain direct evidence that actin cytoskeletal proteins can modulate tumor cell death by regulating disulfidptosis. The gene discussed is DNM2; the disease is cancer.